. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2015 May 14;21(9):1605–1611. doi: 10.1016/j.bbmt.2015.05.007

Table 3. Univariate Analysis^*.

Outcomes	FDG-PET−	FDG-PET+	P Value

	Cumulative Incidence (CI)
Acute GVHD (grade II-IV)
100 Days	26 (20-33)	27 (21-34)	.874
Chronic GVHD
1 Year	43 (36-51)	43 (36-51)	.997
3 Years	52 (44-59)	54 (46-62)	.717
NRM
1 Year	19 (13-25)	14 (9-20)	.236
3 Years	27 (20-34)	17 (11-23)	.031
Relapse/progression
1 Year	17 (12-23)	32 (25-40)	.002
3 Years	26 (19-33)	40 (32-48)	.007
PFS
1 Year	64 (57-71)	54 (46-62)	.064
3 Years	47 (40-55)	43 (36-51)	.472
OS
1 Year	75 (68-81)	72 (65-79)	.581
3 Years	60 (52-67)	58 (50-65)	.731

Probabilities of acute GVHD, chronic GVHD, treatment-related mortality, and relapse were calculated using the cumulative incidence estimate. PFS and OS were calculated using the Kaplan-Meier product limit estimate. P values reflect point-wise comparison at defined times.

Table 3. Univariate Analysis*.

Table 3. Univariate Analysis^*.